US 12,186,472 B2
Blood treatment device comprising alkaline phosphatase
Jan Swartjes, Tubingen (DE); Markus Storr, Filderstadt (DE); Martin Rempfer, Gomaringen (DE); Isabelle Litzinger, Hechingen (DE); Stefanie Votteler, Reutlingen (DE); and Philipp Kuhn, Tubingen (DE)
Assigned to GAMBRO LUNDIA AB, Lund (SE)
Appl. No. 17/433,761
Filed by GAMBRO LUNDIA AB, Lund (SE)
PCT Filed Mar. 6, 2020, PCT No. PCT/EP2020/055977
§ 371(c)(1), (2) Date Aug. 25, 2021,
PCT Pub. No. WO2020/178420, PCT Pub. Date Sep. 10, 2020.
Claims priority of application No. 19161050 (EP), filed on Mar. 6, 2019.
Prior Publication US 2022/0241484 A1, Aug. 4, 2022
Int. Cl. A61M 1/36 (2006.01); A61M 1/16 (2006.01); A61M 1/34 (2006.01); B01D 63/02 (2006.01); B01D 69/14 (2006.01); B01D 71/38 (2006.01); B01D 71/42 (2006.01); B01D 71/68 (2006.01); B01D 71/76 (2006.01); B01J 31/00 (2006.01)
CPC A61M 1/3687 (2013.01) [A61M 1/16 (2013.01); A61M 1/3486 (2014.02); A61M 1/3679 (2013.01); B01D 63/031 (2022.08); B01D 63/034 (2022.08); B01D 69/148 (2013.01); B01D 71/383 (2022.08); B01D 71/421 (2022.08); B01D 71/68 (2013.01); B01D 71/76 (2013.01); B01J 31/003 (2013.01); B01D 2323/21825 (2022.08); B01D 2323/2187 (2022.08)] 20 Claims
OG exemplary drawing
 
1. A blood treatment device configured to dephosphorylate one or more substances selected from the group consisting of extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), lipopolysaccharide (LPS), and combinations thereof, in the blood of a patient in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix having alkaline phosphatase (AP) immobilized thereon.
 
14. A method for treating an infection in a patient, said method comprising the step of administering the blood treatment device according to claim 1 to the patient, wherein the blood treatment device transports blood from the vascular system of the patient to the blood treatment device and returns treated blood from the blood treatment device to the patient.